Series B Biotech pitch decks that turn clinical data into conviction.
Series B biotech investors are underwriting clinical data and the strategy to reach a registrational or partnering inflection. The deck must present readouts with rigor, show how the data informs the next trial, and frame pipeline value for specialist and crossover funds.
At a glance
- Typical deck length
- 15–20 slides plus data appendix
- Who you're pitching
- Growth-stage VCs, crossover funds and multi-stage firms writing $15–50M+ checks.
- Lead with
- Clinical results summary · Next-trial design · Regulatory interactions




What Series B Biotech investors need to believe.
A Biotech round at Series B turns on a handful of beliefs. Your deck should build each one before a partner has to ask.
The data is real and differentiated
Clinical results show safety and early efficacy that stand up to the standard of care.
The next trial is de-risked
Dose, population and endpoints for the next study are informed by data in hand.
The pipeline adds value
Additional programs or indications contribute meaningful upside to the story.
There's a path to a strategic outcome
Partnership, licensing or late-stage financing options are credible after the next readout.
What to lead with at Series B.
At this stage, these are the numbers and evidence that carry the room. Each one should tie out to your model and data room.
Clinical results summary
Present safety and efficacy data with appropriate statistics and caveats.
Next-trial design
Show how readouts informed dose, population and endpoint selection.
Regulatory interactions
Summarize agency feedback and designations obtained, if any.
Pipeline value drivers
Show each program's next milestone and its contribution to the opportunity.
Runway and financing plan
Show cash through the next major readout and the financing path beyond.
How to structure a Series B Biotech deck.
A 15–20 slides plus data appendix structure tuned for this round. Tap any slide for the full guide.
-
Title Slide
At Series B, the title slide often anchors on scale — the one-liner states the business you've become and the expansion this round funds.
-
Traction Slide
Lead with clinical data and regulatory progress, presented with honest caveats specialist investors will respect.
Biotech-specific -
Business Model Slide
At Series B, show economics improving with scale: expanding margins, rising revenue per customer and increasingly efficient acquisition.
-
Go-to-Market Slide
At Series B, focus on scaling and expansion — new segments, channels or regions — with evidence that efficiency holds as spend increases.
-
Market Size Slide
At Series B, the market slide should show expansion — adjacent segments, new products or geographies that grow the opportunity beyond the core.
-
Product Slide
At Series B, emphasize roadmap and platform breadth: how new modules or products extend the core and increase revenue per customer.
-
Competition Slide
Show a readout calendar alongside a differentiation table so timing and positioning are clear.
Biotech-specific -
Team Slide
At Series B, the team slide should show a scaling executive team with experience operating at the next stage of growth.
-
Financials Slide
Present cash runway against the clinical calendar, including contingency for trial delays.
Biotech-specific -
The Ask & Use of Funds Slide
At Series B, frame the raise around scaling and expansion — new markets, products or segments — with milestones that set up the next stage or a path to profitability.
What Biotech investors will push on at Series B.
Is the effect size meaningful versus standard of care?
How the deck answers it: Contextualize results against standard-of-care data and explain clinical meaningfulness, not just statistical significance.
Can the company fund a larger trial?
How the deck answers it: Show the financing strategy — this round, partnerships, non-dilutive sources — to reach the next inflection.
What does the competitive readout calendar look like?
How the deck answers it: Map competitor readouts on a timeline and show how you position around them.
Trusted by founders. Backed by results.
They were able to give us insight into a comprehensive and emerging landscape. They provided further resources with case studies and data to make our arguments more compelling; while being timely and communicative. They're an asset to any team moving forward.
[They] were educated in the biopharma space and was able to give us insight into the landscape. They provided further resources/data to make our arguments more compelling. He was timely and communicative. An asset to any team moving forward.
(For our acquisition of Modular Water), they really built the case with deep research. Highly professional. They took the time to work through a number of iterations of the project and maintained outstanding communication. Highly recommend.
Common questions. Clear answers.
How should a Series B biotech deck present clinical data?
Do crossover investors need a different biotech deck?
What does a custom engagement cost?
How fast can you turn it around?
Keep exploring.
Raising your Series B round? Get the deck right first.
Drop your details and we'll send a free deck audit — then jump on a 15-minute intro call to walk through exactly what to fix before you pitch.
- We reply within 24 hours
- Complete founder confidentiality
Got it — your audit is on the way.
We'll review your details and reply within 24 hours. Want to fast-track it? Grab a 15-minute intro call now.
Book your intro call